Profile: Katherine Bowdish, Sanofi’s Early Science Investment Scout
Executive Summary
Katherine Bowdish, vice president of global R&D at Sanofi and leader of Sunrise, the French big pharma's early-stage investment arm, talks to Scrip about living vicariously through biotech companies whilst having the power and backing of a pharma major to advance important, innovative science.
You may also be interested in...
Deal Watch: Celgene The Latest To Buy Into Nimbus’ Computational Chemistry Approach
The big biotech takes options on preclinical Tyk2 and STING programs. REGENXBIO drops out of the bidding for Dimension, ceding to Ultragenyx, and Eisai licenses four drugs to Uruguay’s Grupo Biotoscana.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.